Rani Therapeutics (NASDAQ:RANI) Earns Buy Rating from Analysts at Rodman & Renshaw
Rodman & Renshaw began coverage on shares of Rani Therapeutics (NASDAQ:RANI – Free Report) in a research report released on Thursday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $10.00 target price on the stock. RANI has been the subject of a number of other reports. HC Wainwright lifted their price target […]
More Stories
Iran Signals It May Skip Next US-Led Peace Talks as Israel Warns of Renewed Fighting
By Tom Ozimek Iran signaled fresh uncertainty around U.S.-backed peace efforts on April 20, saying it has yet to decide...
Is Love Story Season 2 Renewed? Release Date, Cast, and Spoiler
Ryan Murphy’s latest series, Love Story Season 1, has raised the bar with the 90’s romance featuring Sarah Pidgeon and...
Fifty Shades of Grey Star, Dakota Johnson, Net Worth and Salary in 2026
The Fifty Shades of Grey lead actress is once again in the spotlight after she appeared kissing her recent boyfriend,...
CapCut Vs InShot: Which is the Best Video Editing Tool?
Videos have become one of the most useful and important tools for every marketing organization. In this digital era, more...
Louisiana Gunman Kills at Least 8 Children in Morning Shooting Spree
By Jacki Thrapp At least eight children were killed during a shooting in Shreveport, Louisiana, on the morning of April...
US to Create 4000-Acre High-Tech Economic Security Zone in the Philippines
By Guy Birchall The United States and the Philippines are set to build a 4,000-acre industrial hub after Manila became...